{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.96","value":"16.8"},{"groupId":"OG001","spread":"12.02","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.39","value":"0.5"},{"groupId":"OG001","spread":"4.86","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Change at Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Mean change from baseline in EORTC QLQ-C30 Index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes","dispersionType":"Standard Deviation","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEAN","populationDescription":"The PD-L1 positive population is defined as a visually estimated combined positive score (vCPS) ≥10%; \"Overall number of participants analyzed\" refers to number of participants evaluable for this outcome measure and \"Number analyzed\" refers to participants evaluable at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Cycle 6 (21 days per cycle)","title":"HRQoL as Assessed by EORTC QLQ-C30 in the PDL-1 Positive Analysis Set","type":"SECONDARY","unitOfMeasure":"Score on a scale"}